Alzheimer’s disease (AD), characterized by the development of neuronal amyloid-β (Aβ1–42) plaques and tau neurofibrillary tangles [1], accounted for 60 to 80% of dementia cases in 2015, affecting 46.8 million people worldwide [2], a number expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050 [3]. This evidence concerns the gene MAPT and Alzheimer disease.